The timing of the government’s forthcoming decision on the legality of Merck’s 340B contract pharmacy policy, and the grounds for its decision, are two big questions hovering over the 340B program.

Attention Turns to Merck and AstraZeneca After Courts’ 340B Contract Pharmacy Rulings

In the wake of federal district judges’ recent decisions in drug manufacturers’ 340B contract pharmacy lawsuits, we are keeping close tabs on what happens next to Merck’s contract pharmacy policy and to AstraZeneca’s contract pharmacy lawsuit.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×